Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14841.203 | 0.0068 | -0.9841 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 2.67 | uM | 14841.203 | 0.0068 | -0.9841 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14841.203 | 0.0116 | -0.9733 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 14841.203 | 0.0116 | -0.9733 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14841.203 | 0.0116 | -0.9731 | 1.0330 | |
| MDA-MB-157 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 14841.203 | 0.0116 | -0.9731 | 1.0330 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7499.074 | 0.9992 | 0.9977 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7499.074 | 0.9992 | 0.9977 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7499.074 | 1.0384 | 1.1069 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7499.074 | 1.0384 | 1.1069 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7499.074 | 1.0120 | 1.0333 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7499.074 | 1.0120 | 1.0333 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7499.074 | 0.5577 | -0.1073 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7499.074 | 0.5577 | -0.1073 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7499.074 | 0.3509 | -0.5293 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7499.074 | 0.3509 | -0.5293 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7499.074 | 0.2807 | -0.6542 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7499.074 | 0.2807 | -0.6542 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7499.074 | 0.1735 | -0.8221 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7499.074 | 0.1735 | -0.8221 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7499.074 | 0.0877 | -0.9307 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7499.074 | 0.0877 | -0.9307 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 7499.074 | 0.1030 | -0.9134 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 7499.074 | 0.1030 | -0.9134 | 0.7239 | |
| MDA-MB-175-VII | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7500.074 | 0.6959 | 0.0064 | 0.5279 |